Skip to main content

Monte Rosa

4634 M

45°56′12.6″N

07°52′01.4″E

QuEEN:

The crown of

drug discovery

Closeup photo of scientist working

QuEEN:

Quantitative and

Engineered Elimination

of Neosubstrates

Our platform is purpose-built to support the discovery and development of drugs that degrade therapeutically relevant proteins by

systematically identifying therapeutically relevant protein targets that may be amenable to MGD-induced degradation, and

rationally designing molecules that can be optimized towards high potency and selectivity.

Central to our QuEEN platform is a detailed understanding of the molecular interactions promoted by our MGDs between ubiquitin ligases and structural features called degrons on the surface of therapeutically relevant proteins

Degrons are elements on proteins that act as ubiquitin ligase recognition signals for protein degradation by the ubiquitin-proteasome system.

01

Degron Encyclopedia

Degron identification using an AI-powered deep neural net

02

Proprietary MGD Library

Rationally designed diverse and growing library of MGDs

03

Glueomics Toolbox

Specialized suite of in vitro and in silico assays to discover, optimize, and advance MGDs as clinical candidates

01

Degron

Encyclopedia

A growing catalogue of target proteins identified through our proprietary artificial intelligence approach that enables us to identify degrons for therapeutically relevant proteins

02

Proprietary

MGD Library

A diverse and continuously growing chemical library of proprietary, drug-like MGDs, rationally designed based on our expertise in basic glue anatomy

03

Glueomics

Toolbox

A tailored suite of biochemical, structural biology, cellular, proteomics, and in silico tools that enable the discovery and optimization of MGD product candidates that efficiently recruit degron-containing target proteins, also called neosubstrates, to ubiquitin ligases

Photo of 3 vials of red fluid
Closeup on a scientist working

Biomarker-driven

precision medicine

We focus on therapeutic targets backed by strong biological and genetic rationale with the goal of discovering and developing novel precision medicines. Our internal discovery programs are focused on therapeutically relevant targets, including those that have been considered undruggable.

Pipeline

Our pipeline of MGDs represents a new approach to selectively eliminate therapeutically relevant proteins in cancer and beyond

Target/Program

Indication(s)

Discovery

IND Enabling

Phase 1

Phase 2

Phase 3

GSPT1

NSCLC, SCLC, Heme Malignancies

NEK7

Inflammatory Diseases

CDK2

Ovarian Cancer,
Breast Cancer

VAV1

T and B Cell Malignancies,
Autoimmune Disease

BCL11A

SCD, β-Thalassemia

Undisclosed

Multiple

Oncology

Inflammatory

Oncology / Immunology

Genetic diseases